COMP <GO>
IMA vs INMB // EV/EBITDA & P/E VALUATION
ImageneBio Inc. (NASDAQ) VS. INmune Bio Inc. (NASDAQ) • 15-METRIC TALLY: IMA 2
— INMB 2
■ METRIC PARITY
LAST: $4.05 (-3.57%) • MKT CAP: $46.0M
valuation
—
LAST: $1.60 (+4.58%) • MKT CAP: $44.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMA VS. INMB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMA | INMB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 180.00% | -245.00 | INMB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | INMB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.3 | 34.5 | +5.78 | IMA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $46.0M | $44.4M | $1.6M | IMA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMA REV | INMB REV | IMA GROSS % | INMB GROSS % | IMA FCF | INMB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $800.0K | $50.0K | — | — | -$47.8M | -$23.6M |
| FY 2024 | $3.5M | $14.0K | — | — | -$21.3M | -$33.4M |
| FY 2023 | $9.2M | $155.0K | — | — | -$79.7M | -$12.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMA // BETA —
INMB // BETA —